La “FUNDACION ESPAÑOLA PARA LA CURACION DE LA LEUCEMIA MIELOIDE CRONICA”, participa activamente en el avance científico de la curación de la enfermedad, actualmente, la investigación se centra en la búsqueda de otros genes que pueden influir en el desarrollo de la enfermedad.

LISTADO DE PUBLICACIONES MÁS RELEVANTES DEL GELMC (Grupo Español de Leucemia Mieloide Crónica) años 2010-2015.

• Earlyintervention during imatinib therapy in patients with newly diagnosed chronic-phasechronic myeloid leukemia: a study of the Spanish PETHEMA group. Cervantes F, Lopez-Garrido P, Montero MI, Jonte F, Martinez J, Hernandez-Boluda JC, Calbacho M, Sureda A, Perez-Rus G, Nieto JB, Perez-Lopez C, Roman-Gomez J, Gonzalez M, Pereira A, Colomer D. Haematologica. 2010 Aug; 95(8):1317-24. Epub 2010 Mar 10. PMID: 20220063. PMCID: PMC2913080 DOI:10.3324/haematol.2009.021154
• Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Guilhot J, Baccarani M, Clark RE, Cervantes F, Guilhot F, Hochhaus A, Kulikov S, Mayer J, Petzer AL, Rosti G, Rousselot P, Saglio G, Saussele S, Simonsson B, Steegmann JL, Zaritskey A, Hehlmann R. Blood. 2012 Jun 21; 119(25):5963-71. Epub 2012 Apr 16. PMID: 22508936. DOI: 10.1182/blood-2011-10-383711
• Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Steegmann JL, Cervantes F, le Coutre P, Porkka K, Saglio G. Leuk Lymphoma. 2012 Dec; 53(12):2351-61. Epub 2012 Jun 18. Review. PMID: 22616642. DOI: 10.3109/10428194.2012.695779
• European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R. Blood. 2013 Aug 8; 122(6):872-84. Epub 2013 Jun 26. Review. PMID: 23803709. PMCID: PMC4915804. DOI: 10.1182/blood-2013-05-501569

• Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqué C, Chuah C, Pavlovsky C, Mayer J, Cortes J, Baccarani M, Kim DW, Bradley-Garelik MB, Mohamed H, Wildgust M, Hochhaus A. Blood. 2014 Jan 23; 123(4):494-500. Epub 2013 Dec 5. PMID: 24311723. PMCID: PMC4190618. DOI: 10.1182/blood-2013-06-511592

• Do chronic myeloid leukemia patients with late «warning» responses benefit from «watch and wait» or switching therapy to a second generation tyrosine kinase inhibitor? Garcia-Gutierrez V, Puerta JM, Maestro B, Casado Montero LF, Muriel A, Molina Hurtado JR, Perez-Encinas M, Moreno Romero MV, Sunol PB, Sola Garcia R, De Paz R, Ramirez Sanchez MJ, Osorio S, Mata Vazquez MI, Martinez Lopez J, Sastre JL, Portero Mde L, Bautista G, Duran Nieto MS, Giraldo P, Jimenez Jambrina M, Burgaleta C, Ruiz Aredondo J, Penarrubia MJ, Requena MJ, Fernandez Valle Mdel C, Calle C, Paz Coll A, Hernandez-Rivas JA, Franco Osorio R, Cano P, Tallon Perez D, Fernandez de la Mata M, Garrido PL, Steegmann JL. Am J Hematol. 2014 Nov; 89(11):E206-11. Epub 2014 Aug 27. PMID: 25059397. DOI:10.1002/ajh.23816
• Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months. Casado LF, Garcia-Gutierrez JV, Massague I, Giraldo P, Perez-Encinas M, de Paz R, Martinez-Lopez J, Bautista G, Osorio S, Requena MJ, Palomera L, Penarrubia MJ, Calle C, Hernandez-Rivas JA, Burgaleta C, Maestro B, Garcia-Ormena N, Steegmann JL. Cancer Med. 2015 Jul; 4(7):995-1002. Epub 2015 Mar 10. PMID: 25756742. PMCID:PMC4529338 DOI:10.1002/cam4.440

• Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line.Results of the Spanish compassionate use program. García-Gutiérrez V, Martinez-Trillos A, Lopez Lorenzo JL, Bautista G, Martin Mateos ML, Alvarez-Larrán A, Iglesias Pérez A, Romo Collado A, Fernandez A, Portero A, Cuevas B, Ruiz C, Romero E, Ortega F, Mata I, Tallón J, García Garay Mdel C, Ramirez Sánchez MJ, de Las Heras N, Giraldo P, Bobillo S, Guinea JM, Deben G, Valencia S, Sebrango A, Boqué C, Maestro B, Steegmann JL. Am J Hematol. 2015 May; 90(5):429-33. Epub 2015 Mar 30.PMID: 25683327. DOI:10.1002/ajh.23973